A Win For Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ) jumped higher at $0.62, representing a gain of 35.4%. On Wed, Jan 11, 2023, HEPA:NASDAQ hit a New 2-Week High of $0.62. The stock appeared on our News Catalysts scanner on Tue, Jan 10, 2023 at 05:02 PM in the 'MERGER' category. From Wed, Dec 28, 2022, the stock recorded 55.56% Up Days and 70.00% Green Days
About Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ)
ContraVir Pharmaceuticals Inc is a United States-based biopharmaceutical company engaged in the development of targeted pharmaceutical therapies for liver disease. The company focuses on developing two novel oral compounds to treat HBV infection. CRV431 is a cyclophilin inhibitor that targets specific isomerases that play an important role in protein folding in health and in disease. TXL is a nucleotide pro-drug of tenofovir that inhibits hepatitis B viral replication and targets the liver, the reservoir for the hepatitis B virus.
Top 10 Gainers:
- Atlis Motor Vehicles Inc. (AMV:NASDAQ), 276.12%
- Broadwind Energy, Inc. (BWEN:NASDAQ), 96.9%
- Bed Bath & Beyond Inc. (BBBY:NASDAQ), 68.6%
- Ontrak Inc. (OTRK:NASDAQ), 39.11%
- Laser Photonics Corporation (LASE:NASDAQ), 38.34%
- Scopus BioPharma Inc. (SCPS:NASDAQ), 35.56%
- Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ), 35.42%
- NextPlay Technologies Inc. (NXTP:NASDAQ), 35.08%
- Trxade Group, Inc. (MEDS:NASDAQ), 34.09%
- Inotiv Inc. (NOTV:NASDAQ), 31.31%